These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706 [TBL] [Abstract][Full Text] [Related]
5. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study. Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445 [TBL] [Abstract][Full Text] [Related]
6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
7. Baseline Characteristics of the VANISH Cohort. Axelsson Raja A; Shi L; Day SM; Russell M; Zahka K; Lever H; Colan SD; Margossian R; Hall EK; Becker J; Jefferies JL; Patel AR; Choudhury L; Murphy AM; Canter C; Bach R; Taylor M; Mestroni L; Wheeler MT; Benson L; Owens AT; Rossano J; Lin KY; Pahl E; Pereira AC; Bundgaard H; Lewis GD; Vargas JD; Cirino AL; McMurray JJV; MacRae CA; Solomon SD; Orav EJ; Braunwald E; Ho CY Circ Heart Fail; 2019 Dec; 12(12):e006231. PubMed ID: 31813281 [TBL] [Abstract][Full Text] [Related]
8. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms and medical management of exercise intolerance in hypertrophic cardiomyopathy. Patel V; Critoph CH; Elliott PM Curr Pharm Des; 2015; 21(4):466-72. PubMed ID: 25483947 [TBL] [Abstract][Full Text] [Related]
10. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. Coats CJ; Pavlou M; Watkinson OT; Protonotarios A; Moss L; Hyland R; Rantell K; Pantazis AA; Tome M; McKenna WJ; Frenneaux MP; Omar R; Elliott PM JAMA Cardiol; 2019 Mar; 4(3):230-235. PubMed ID: 30725091 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial). Ananthakrishna R; Lee SL; Foote J; Sallustio BC; Binda G; Mangoni AA; Woodman R; Semsarian C; Horowitz JD; Selvanayagam JB Am Heart J; 2021 Oct; 240():101-113. PubMed ID: 34175315 [TBL] [Abstract][Full Text] [Related]
12. Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Axelsson A; Iversen K; Vejlstrup N; Ho CY; Havndrup O; Kofoed KF; Norsk J; Jensen M; Bundgaard H Heart; 2016 Feb; 102(4):285-91. PubMed ID: 26661322 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Klempfner R; Kamerman T; Schwammenthal E; Nahshon A; Hay I; Goldenberg I; Dov F; Arad M Eur J Prev Cardiol; 2015 Jan; 22(1):13-9. PubMed ID: 23928567 [TBL] [Abstract][Full Text] [Related]